Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 265

1.

Risk score for intracranial hemorrhage in patients with acute ischemic stroke treated with intravenous tissue-type plasminogen activator.

Menon BK, Saver JL, Prabhakaran S, Reeves M, Liang L, Olson DM, Peterson ED, Hernandez AF, Fonarow GC, Schwamm LH, Smith EE.

Stroke. 2012 Sep;43(9):2293-9. doi: 10.1161/STROKEAHA.112.660415. Epub 2012 Jul 17.

2.

Comparison of risk-scoring systems in predicting symptomatic intracerebral hemorrhage after intravenous thrombolysis.

Sung SF, Chen SC, Lin HJ, Chen YW, Tseng MC, Chen CH.

Stroke. 2013 Jun;44(6):1561-6. doi: 10.1161/STROKEAHA.111.000651. Epub 2013 Apr 30.

3.

Predicting the risk of symptomatic intracerebral hemorrhage in ischemic stroke treated with intravenous alteplase: safe Implementation of Treatments in Stroke (SITS) symptomatic intracerebral hemorrhage risk score.

Mazya M, Egido JA, Ford GA, Lees KR, Mikulik R, Toni D, Wahlgren N, Ahmed N; SITS Investigators.

Stroke. 2012 Jun;43(6):1524-31. doi: 10.1161/STROKEAHA.111.644815. Epub 2012 Mar 22. Erratum in: Stroke. 2012 Sep;43(9):e102.

4.

Symptomatic intracerebral hemorrhage after intravenous thrombolysis in Chinese patients: comparison of prediction models.

Li M, Wang-Qin RQ, Wang YL, Liu LB, Pan YS, Liao XL, Wang YJ, Xu AD.

J Stroke Cerebrovasc Dis. 2015 Jun;24(6):1235-43. doi: 10.1016/j.jstrokecerebrovasdis.2015.01.026. Epub 2015 Apr 16.

PMID:
25891755
5.

Targeting recombinant tissue-type plasminogen activator in acute ischemic stroke based on risk of intracranial hemorrhage or poor functional outcome: an analysis of the third international stroke trial.

Whiteley WN, Thompson D, Murray G, Cohen G, Lindley RI, Wardlaw J, Sandercock P; IST-3 Collaborative Group.

Stroke. 2014 Apr;45(4):1000-6. doi: 10.1161/STROKEAHA.113.004362. Epub 2014 Mar 6.

6.

Pretreatment hemostatic markers of symptomatic intracerebral hemorrhage in patients treated with tissue plasminogen activator.

Cocho D, Borrell M, Martí-Fàbregas J, Montaner J, Castellanos M, Bravo Y, Molina-Porcel L, Belvís R, Díaz-Manera JA, Martínez-Domeño A, Martínez-Lage M, Millán M, Fontcuberta J, Martí-Vilalta JL.

Stroke. 2006 Apr;37(4):996-9. Epub 2006 Feb 23.

7.

Posttreatment variables improve outcome prediction after intra-arterial therapy for acute ischemic stroke.

Prabhakaran S, Jovin TG, Tayal AH, Hussain MS, Nguyen TN, Sheth KN, Terry JB, Nogueira RG, Horev A, Gandhi D, Wisco D, Glenn BA, Ludwig B, Clemmons PF, Cronin CA, Tian M, Liebeskind D, Zaidat OO, Castonguay AC, Martin C, Mueller-Kronast N, English JD, Linfante I, Malisch TW, Gupta R.

Cerebrovasc Dis. 2014;37(5):356-63. doi: 10.1159/000362591. Epub 2014 Jun 18.

8.

Pre-tissue plasminogen activator blood pressure levels and risk of symptomatic intracerebral hemorrhage.

Tsivgoulis G, Frey JL, Flaster M, Sharma VK, Lao AY, Hoover SL, Liu W, Stamboulis E, Alexandrov AW, Malkoff MD, Alexandrov AV.

Stroke. 2009 Nov;40(11):3631-4. doi: 10.1161/STROKEAHA.109.564096. Epub 2009 Sep 17.

9.

Symptomatic intracranial hemorrhage following intravenous thrombolysis for acute ischemic stroke: a critical review of case definitions.

Seet RC, Rabinstein AA.

Cerebrovasc Dis. 2012;34(2):106-14. doi: 10.1159/000339675. Epub 2012 Aug 1. Review.

10.

The THRIVE score predicts symptomatic intracerebral hemorrhage after intravenous tPA administration in SITS-MOST.

Flint AC, Gupta R, Smith WS, Kamel H, Faigeles BS, Cullen SP, Rao VA, Bath PM, Wahlgren N, Ahmed N, Donnan GA; SITS International and VISTA-plus investigators.

Int J Stroke. 2014 Aug;9(6):705-10. doi: 10.1111/ijs.12335. Epub 2014 Jul 15.

PMID:
25042855
11.

External validation of the SEDAN score for prediction of intracerebral hemorrhage in stroke thrombolysis.

Mazya MV, Bovi P, Castillo J, Jatuzis D, Kobayashi A, Wahlgren N, Ahmed N.

Stroke. 2013 Jun;44(6):1595-600. doi: 10.1161/STROKEAHA.113.000794. Epub 2013 Apr 30.

12.

Frequency and predictors of symptomatic intracerebral hemorrhage in patients with ischemic stroke treated with recombinant tissue plasminogen activator outside clinical trials.

Martí-Fàbregas J, Bravo Y, Cocho D, Martí-Vilalta JL, Díaz-Manera J, San Román L, Puig M, Blanco M, Castellanos M, Millán M, Roquer J, Obach V, Maestre J.

Cerebrovasc Dis. 2007;23(2-3):85-90. Epub 2006 Nov 15.

PMID:
17114877
13.

Lipid profile, lipid-lowering medications, and intracerebral hemorrhage after tPA in get with the guidelines-stroke.

Messé SR, Pervez MA, Smith EE, Siddique KA, Hellkamp AS, Saver JL, Bhatt DL, Fonarow GC, Peterson ED, Schwamm LH.

Stroke. 2013 May;44(5):1354-9. doi: 10.1161/STROKEAHA.111.671966. Epub 2013 Mar 14.

14.

Safety of antiplatelet therapy prior to intravenous thrombolysis in acute ischemic stroke.

Uyttenboogaart M, Koch MW, Koopman K, Vroomen PC, De Keyser J, Luijckx GJ.

Arch Neurol. 2008 May;65(5):607-11. doi: 10.1001/archneur.65.5.noc70077. Epub 2008 Mar 10.

PMID:
18332238
15.

Intravenous tissue-type plasminogen activator therapy is an independent risk factor for symptomatic intracerebral hemorrhage after carotid endarterectomy.

Vellimana AK, Yarbrough CK, Blackburn S, Strom RG, Pilgram TK, Lee JM, Grubb RL Jr, Rich KM, Chicoine MR, Dacey RG Jr, Derdeyn CP, Zipfel GJ.

Neurosurgery. 2014 Mar;74(3):254-61. doi: 10.1227/NEU.0000000000000261.

16.

Risk of symptomatic intracerebral hemorrhage in patients treated with intra-arterial thrombolysis.

Singer OC, Berkefeld J, Lorenz MW, Fiehler J, Albers GW, Lansberg MG, Kastrup A, Rovira A, Liebeskind DS, Gass A, Rosso C, Derex L, Kim JS, Neumann-Haefelin T; MR Stroke Study Group Investigators.

Cerebrovasc Dis. 2009;27(4):368-74. doi: 10.1159/000202427. Epub 2009 Feb 16.

17.

Multivariable analysis of outcome predictors and adjustment of main outcome results to baseline data profile in randomized controlled trials: Safe Implementation of Thrombolysis in Stroke-MOnitoring STudy (SITS-MOST).

Wahlgren N, Ahmed N, Eriksson N, Aichner F, Bluhmki E, Dávalos A, Erilä T, Ford GA, Grond M, Hacke W, Hennerici MG, Kaste M, Köhrmann M, Larrue V, Lees KR, Machnig T, Roine RO, Toni D, Vanhooren G; Safe Implementation of Thrombolysis in Stroke-MOnitoring STudy Investigators.

Stroke. 2008 Dec;39(12):3316-22. doi: 10.1161/STROKEAHA.107.510768. Epub 2008 Oct 16.

18.

Intravenous thrombolysis in young stroke patients: results from the SITS-ISTR.

Toni D, Ahmed N, Anzini A, Lorenzano S, Brozman M, Kaste M, Mikulik R, Putaala J, Wahlgren N; SITS investigators.

Neurology. 2012 Mar 20;78(12):880-7. doi: 10.1212/WNL.0b013e31824d966b. Epub 2012 Mar 7.

PMID:
22402853
19.

Tissue plasminogen activator thrombolytic therapy for acute ischemic stroke in 4 hospital groups in Japan.

Kono S, Deguchi K, Morimoto N, Kurata T, Deguchi S, Yamashita T, Ikeda Y, Matsuura T, Narai H, Omori N, Manabe Y, Yunoki T, Takao Y, Kawata S, Kashihara K, Abe K.

J Stroke Cerebrovasc Dis. 2013 Apr;22(3):190-6. doi: 10.1016/j.jstrokecerebrovasdis.2011.07.016. Epub 2011 Oct 2.

PMID:
21968092
20.

Patient outcomes from symptomatic intracerebral hemorrhage after stroke thrombolysis.

Strbian D, Sairanen T, Meretoja A, Pitkäniemi J, Putaala J, Salonen O, Silvennoinen H, Kaste M, Tatlisumak T; Helsinki Stroke Thrombolysis Registry Group.

Neurology. 2011 Jul 26;77(4):341-8. doi: 10.1212/WNL.0b013e3182267b8c. Epub 2011 Jun 29.

PMID:
21715707

Supplemental Content

Support Center